GILD (Gilead Sciences Inc)
Insider Trading Activity
Every open-market purchase and sale reported by GILD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Daniel Patrick O'Day | Chairman & CEO | Sell | — | — |
| 2026-08-27 | ANTHONY WELTERS | Director | MIXED | — | — |
| 2026-08-21 | Jeffrey Bluestone | Director | MIXED | — | — |
| 2026-08-18 | Andrew D Dickinson | Chief Financial Officer | Sell | — | — |
| 2026-08-18 | Johanna Mercier | Chief Comm & Corp Aff Officer | MIXED | — | — |
| 2026-08-11 | Wettan Keeley M Cain | EVP Gen Counsel, Legal & Comp | MIXED | — | — |
| 2026-08-04 | Daniel Patrick O'Day | Chairman & CEO | Sell | — | — |
| 2026-07-16 | Andrew D Dickinson | Chief Financial Officer | Sell | — | — |
| 2026-07-16 | Johanna Mercier | Chief Comm & Corp Aff Officer | Sell | — | — |
| 2026-07-02 | Daniel Patrick O'Day | Chairman & CEO | Sell | — | — |
| 2026-06-16 | Andrew D Dickinson | Chief Financial Officer | Sell | — | — |
| 2026-06-16 | Johanna Mercier | Chief Comm & Corp Aff Officer | Sell | — | — |
| 2026-06-11 | Dietmar Berger | Chief Medical Officer | MIXED | — | — |
| 2026-06-11 | Wettan Keeley M Cain | EVP Gen Counsel, Legal & Comp | MIXED | — | — |
| 2026-06-11 | Daniel Patrick O'Day | Chairman & CEO | MIXED | — | — |
| 2026-06-11 | Johanna Mercier | Chief Comm & Corp Aff Officer | MIXED | — | — |
| 2026-06-11 | Andrew D Dickinson | Chief Financial Officer | MIXED | — | — |
| 2026-06-02 | Daniel Patrick O'Day | Chairman & CEO | Sell | — | — |
| 2026-05-18 | Johanna Mercier | Chief Comm & Corp Aff Officer | MIXED | — | — |
| 2026-05-18 | Andrew D Dickinson | Chief Financial Officer | Sell | — | — |
| 2026-05-04 | Kelly A. Kramer | Director | A | — | — |
| 2026-05-04 | HARISH MANWANI | Director | MIXED | — | — |
| 2026-05-04 | ANTHONY WELTERS | Director | A | — | — |
| 2026-05-04 | Javier Rodriguez | Director | A | — | — |
| 2026-05-04 | TED W LOVE | Director | A | — | — |
| 2026-05-04 | Sandra Horning | Director | A | — | — |
| 2026-05-04 | JACQUELINE K BARTON | Director | A | — | — |
| 2026-05-04 | Jeffrey Bluestone | Director | A | — | — |
| 2026-04-29 | Daniel Patrick O'Day | Chairman & CEO | Sell | — | — |
| 2026-04-16 | Johanna Mercier | Chief Comm & Corp Aff Officer | Sell | — | — |
| 2026-04-16 | Andrew D Dickinson | Chief Financial Officer | Sell | — | — |
| 2026-03-30 | Daniel Patrick O'Day | Chairman & CEO | Sell | — | — |
| 2026-03-17 | Andrew D Dickinson | Chief Financial Officer | Sell | — | — |
| 2026-03-17 | Johanna Mercier | Chief Comm & Corp Aff Officer | Sell | — | — |
| 2026-03-12 | Dietmar Berger | Chief Medical Officer | MIXED | — | — |
| 2026-03-12 | Daniel Patrick O'Day | Chairman & CEO | MIXED | — | — |
| 2026-03-12 | Erin Burkhart | SVP, Controllership | A | — | — |
| 2026-03-12 | Wettan Keeley M Cain | EVP Gen Counsel, Legal & Comp | MIXED | — | — |
| 2026-03-12 | Johanna Mercier | Chief Comm & Corp Aff Officer | MIXED | — | — |
| 2026-03-12 | Andrew D Dickinson | Chief Financial Officer | MIXED | — | — |
| 2026-03-02 | Daniel Patrick O'Day | Chairman & CEO | MIXED | — | — |
| 2026-03-02 | Wettan Keeley M Cain | EVP Gen Counsel, Legal & Comp | A | — | — |
| 2026-03-02 | Dietmar Berger | Chief Medical Officer | A | — | — |
| 2026-03-02 | Johanna Mercier | Chief Comm & Corp Aff Officer | A | — | — |
| 2026-03-02 | Andrew D Dickinson | Chief Financial Officer | A | — | — |
| 2026-02-18 | Andrew D Dickinson | Chief Financial Officer | Sell | — | — |
| 2026-02-18 | Johanna Mercier | Chief Comm & Corp Aff Officer | MIXED | — | — |
| 2026-02-06 | Daniel Patrick O'Day | Chairman & CEO | MIXED | — | — |
| 2026-02-05 | Daniel Patrick O'Day | Chairman & CEO | MIXED | — | — |
| 2026-02-05 | Andrew D Dickinson | Chief Financial Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 3,619,142 | — |
| — | Director | 3,234,674 | — |
| — | EVP, R&D and CSO | 2,346,795 | — |
| — | President and CEO | 1,797,816 | — |
| — | Director | 838,652 | — |
| — | Director | 616,116 | — |
| — | SVP, Research | 614,644 | — |
| — | SVP, Pharm Dev & Mfg | 606,692 | — |
| — | Chairman & CEO | 582,541 | — |
| — | Director | 329,052 | — |
| — | Chief Financial Officer | 165,646 | — |
| — | EVP Worldwide Commercial Ops | 139,865 | — |
| — | EVP, CFO | 138,613 | — |
| — | Chief Comm & Corp Aff Officer | 118,234 | — |
| — | SVP, Clinical Research | 114,256 | — |
| — | Director | 102,060 | — |
| — | Director | 101,095 | — |
| — | Chief Medical Officer | 84,621 | — |
| — | Director | 71,640 | — |
| — | EVP Commercial Ops | 64,305 | — |
| — | Chief Patient Officer | 58,046 | — |
| — | Director | 54,860 | — |
| — | SVP, Human Resources | 50,610 | — |
| — | Interim Corp Controller & CAO | 46,259 | — |
| — | EVP, Corporate Affairs & GC | 43,676 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GILD quote page; the site-wide leaderboard is on the insider transactions hub.